Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its 
receptor (CLR + RAMP1) offer considerable improvements over existing drugs in 
migraine prophylaxis and are the first designed to act on the trigeminal pain 
system. Erenumab is approved by the FDA and EMA and has reached the market since 
May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the 
CGRP ligand, were approved by the FDA in September 2018. To view this Bench to 
Bedside, open or download the PDF.